Evaxion A/S Advances Personalized Cancer Vaccine Program
Evaxion A/S (NASDAQ: EVAX) has completed a one‑year extension of its phase‑2 clinical trial for the personalized melanoma vaccine EVX‑01. The last patient visit was reported on April 7, 2026, and the company anticipates presenting three‑year efficacy data in the second half of the year.
Trial Design and Progress
The expanded study builds on an earlier two‑year cohort that combined EVX‑01 with Merck’s anti‑PD‑1 antibody Keytruda (pembrolizumab). In the third year, patients received EVX‑01 as monotherapy, allowing investigators to assess both combination and stand‑alone efficacy. Patient monitoring will continue beyond the last visit, with data preparation underway for the upcoming presentation.
Early Clinical Outcomes
Results from the first two years are already striking:
| Metric | Result |
|---|---|
| Objective Response Rate (ORR) | 75 % (12 of 16 patients) |
| Complete Responses | 4 |
| Durable Benefit at 2 years | 92 % |
| Deepening Responses | 54 % of patients shifted from stable/partial to partial/complete |
| Tumor Reduction | 15 of 16 patients showed target lesion shrinkage |
| Immune Response | 81 % of targeted neoantigens elicited potent T‑cell activity |
| Tolerability | Well‑tolerated with no relapses reported |
These data underscore the platform’s capacity to identify highly immunogenic neoantigens and to sustain antitumor responses over time.
Strategic Implications
The successful extension demonstrates the robustness of Evaxion’s AI‑Immunology platform and its translational potential. By proving efficacy as both a combination therapy and a monotherapy, the company strengthens its case for broader regulatory engagement and potential partnership opportunities. The forthcoming three‑year dataset will be pivotal in validating long‑term benefit and informing future trial designs, including the off‑the‑shelf vaccine candidates currently in the pipeline.
Market Context
With a market capitalization of approximately $31 million and a recent closing price of $3.73, Evaxion remains a niche biotech play. Its price‑earnings ratio of –3.15 reflects the early‑stage nature of its operations. However, the compelling clinical signal and the company’s proprietary AI platform position it as a forward‑looking candidate in the oncology vaccine space.
Outlook
If the third‑year data confirm sustained durability and broadened efficacy, Evaxion could secure pivotal regulatory milestones and attract strategic collaborations. The company’s focus on AI‑driven precision oncology aligns with broader industry trends toward personalized therapeutics, potentially catalyzing further investment and growth.
Prepared with data sourced from Evaxion A/S fundamentals and the latest press releases dated April 7, 2026.
